Nick McFarland

Nick McFarland MD, PhD

Associate Professor

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-5550

About Nick McFarland

Nikolaus McFarland, MD, PhD, joined the UF Department of Neurology and the UF Health Center for Movement Disorders & Neurorestoration in 2010. He graduated from the University of Chicago in 1992 with honors in biology and election into the Sigma Xi research society. He completed medical and graduate training in the MD-PhD program at the University of Rochester School of Medicine & Dentistry, where he received a merit award for outstanding graduate research in basal ganglia-thalamic anatomy. Afterwards, he went to the University of Virginia for internship and residency training in neurology, and then pursued fellowship training in movement disorders at the Massachusetts General Hospital. While a fellow and junior faculty member at MGH/Harvard he pursued research in Parkinson disease and related disorders. As a Udall Fellow, he became the first recipient of the Robert Koch Parkinson Disease research fellowship. He has since received research grant support from the American Parkinson Disease Association, Michael J. Fox Foundation, and the National Institutes of Health.

Honors & Awards

Fellow Member of the American Academy of Neurology
2017 · American Academy of Neurology
UF Excellence Award for Assistant Professors
2014 · University of Florida College of Medicine
Wright/Falls/Simmons Professorship in PSP/Atypical Parkinson’s disease
2013 · University of Florida College of Medicine
Didactic Teacher of the Year Award
2013 · University of Florida, Neurology Residents
Robert N. Koch Jr. Fellowship in Parkinson’s Disease Research
2008 · Massachusetts General Hospital
Neurology Resident Teaching Award
2006 · University of Virginia Health System, Neurology Department
Udall Fellowship in Movement Disorders
2006 · Massachusetts General Hospital

Board Certifications

Neurology
ABPN

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Basal ganglia dysfunction
  • Deep brain stimulation
  • Dystonia
  • Essential tremor
  • Movement – uncontrollable
  • Movement – uncontrolled or slow
  • Movement – uncoordinated
  • Movement – unpredictable or jerky
  • Parkinson disease
  • Progressive supranuclear palsy
  • Tremor
  • Multiple system atrophy – parkinsonian type
  • Huntington disease

Research Profile

Dr. McFarland is an active member of the Center for Translational Research in Neurodegenerative Disease (CTRND) which aims to bring the bench closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and in particular the role of alpha-synuclein in cell toxicity and neurodegeneration. His current studies utilize both cellular and preclinical models to study genes and molecules that may affect brain pathology. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.

Publications

2015 Journal of Clinical and Experimental Neuropsychology

Grants

January 2019ACTIVE
Huntingtons Disease Society of America Centers of Excellence Program
HUNTINGTONS DISEASE SOCIETY OF AMERICA · Principal Investigator
July 2018 – June 2019
Huntingtons Disease Society of America Centers of Excellence Program
HUNTINGTONS DISEASE SOCIETY OF AMERICA · Principal Investigator
January 2018ACTIVE
Proteinopathy in Atypical Parkinson disorders
UF FOU · Principal Investigator
September 2017ACTIVE
Neuroimaging Biomarkers in Parkinsonism: Differentiating Subtypes and Tracking Disease Progression
NATL INST OF HLTH NINDS ·
July 2017 – June 2018
Huntingtons Disease Society of America Centers of Excellence Program
HUNTINGTONS DISEASE SOCIETY OF AMERICA · Principal Investigator
June 2017 – June 2018
Parkinson Foundation Center of Excellence
NATL PARKINSON FOU ·
May 2017ACTIVE
Role of HLA/MHCII in Parkinson's Disease Pathogenesis
EMORY UNIV · Principal Investigator
January 2017ACTIVE
Targeting Synucleinopathy in Multiple System Atrophy Parkinsonism
UF FOU · Principal Investigator
August 2016ACTIVE
Scaling and Sequencing Motor Output in Humans: fMRI Study
NATL INST OF HLTH NINDS ·
July 2016 – June 2017
National Parkinson Foundation (NPF) Center of Excellence
NATL PARKINSON FOU ·
July 2016 – June 2017
Huntington?s Disease Society of America Centers of Excel
HUNTINGTONS DISEASE SOCIETY OF AMERICA · Principal Investigator
February 2016 – February 2022
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously AdministeredBMS-986168 in Patients with Progressive Supranuclear Palsy Who Participated inStudy CN002003
BRISTOL MYERS SQUIBB CO · Principal Investigator
December 2015 – April 2017
TARGETING RER1 IN MODELS OF PARKINSON'S DISEASE
FOX FOU, MICHAEL J · Principal Investigator
September 2015 – September 2018
a randomized double blind placebo controlled multiple
COVANCE INC · Principal Investigator
July 2015ACTIVE
Role of Cortex and Cerbellum in Visually-Guided Motor Behavior
NATL INST OF HLTH NINDS · Project Manager
May 2015 – June 2019
RAB PROTEINS AND ALPHA
FL CLINICAL PRACTICE ASSO · Principal Investigator
September 2013 – August 2019
White Matter Connectivity and PD Cognitive Phenotypes
NATL INST OF HLTH NINDS ·
August 2010 – July 2016
Rab proteins and alpha-Synuclein toxicity in Neurodegene
NATL INST OF HLTH NINDS · Principal Investigator